The U.S. Department of Health and Human Services (HHS) has submitted a policy plan to the White House to approve peptide medications in pharmacies. This initiative is a priority for Robert F. Kennedy Jr. since he became the head of HHS.
Peptide Drugs Approval: Recently, the Food and Drug Administration (FDA) approved six peptide drugs. HHS is now seeking approval from President Trump's Office of Management and Budget (OMB) to allow these peptides to be compounded in select pharmacies.
Support for Peptides: The American Academy of Peptide Medicine (AAPM) is behind the request. Lee Rosebush, AAPM’s chair, expressed optimism about the approval process, emphasizing the need for safe access to these medications and the importance of eliminating black market sales.
AAPM Overview: Founded in 2025, AAPM is a nonprofit focused on promoting the responsible use of peptide therapies. It aims to gather professionals committed to this growing medical field.
Regulatory Background: In September 2023, a decision by the Biden administration categorized many peptides as high-risk, contributing to illegal market issues. The FDA is expected to reassess these substances in upcoming meetings.
Potential Benefits of Peptides: Peptides, composed of amino acids, offer various health benefits, targeting specific medical needs and minimizing side effects. They are commonly administered through injections and can aid in fat loss, muscle growth, cognitive performance, and hormonal balance.
Ongoing Efforts: Kennedy has publicly stated his commitment to ensuring patients have regulated access to peptide medications, further highlighting the importance of following scientific evidence in the approval process.
The action plan for peptide drugs by HHS represents a significant step toward increasing access to alternative medicines. With the involvement of AAPM and other stakeholders, there is hope for a safe, regulated pathway for peptides that could benefit many patients. The situation is evolving as the OMB reviews the request, and anticipation builds for a favorable outcome that can shift peptide access away from illicit markets.
https://dailycaller.com/2026/10/16/rfk-jr-peptides-pharmacies-hhs-action-plans/
No comments:
Post a Comment